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A dynamic combinatorial library (DCL) screening approach is described that permits direct
identification of the effective (from ineffective) combination of building blocks in the
equilibrating DCL. The approach uses Fourier transform ion cyclotron resonance mass
spectrometry (FTICR MS) together with sustained off-resonance irradiation collision activated
dissociation (SORI-CAD) to detect noncovalent protein-DCL ligand complexes under native
conditions. It was shown that in a single, rapid experiment one could concurrently identify all
the ligands of interest from the DCL against a background of inactive DCL ligands while still
in the presence of the target protein. This result has demonstrated that mass spectrometry may
provide a fast preliminary screening approach to identify DCL candidates for later verification
with more traditional but time-consuming analysis. The MS/MS enables DCL mixtures to be
effectively deconvoluted without the need for either chromatography, synthesis of DCL
sub-libraries, conversion of the DCL to a static library, or disruption of the protein-ligand
complexes before analysis—all typically necessary for the current screening method for
DCLs. (J Am Soc Mass Spectrom 2006, 17, 1074–1080) © 2006 American Society for Mass
SpectrometryDynamic combinatorial chemistry (DCC) hasadded a new dimension to the synthetic capa-bility of combinatorial chemistry by allowing
the combinatorial synthesis to occur through reversible
covalent reactions [1–3]. The benefit of this additional
dimension becomes readily evident when dynamic
combinatorial libraries (DCLs) are prepared in the pres-
ence of a therapeutic target molecule. The reversible
chemistry, together with the target acting as a template,
permits self-screening owing to selection and amplifi-
cation of the “best binders” by molecular recognition
events between DCL constituents and the target. There
are now multiple examples of ligand discovery from
dynamic combinatorial libraries (DCLs) generated in
the presence of protein targets [4 –20]. In principle, DCC
has the potential to circumvent the need to individually
synthesize, characterize, and screen each possible li-
brary constituent, however rapid detection of the en-
riched DCL product(s) still poses a serious analytical
problem and is a critical limitation to DCC taking a
prominent place in drug discovery [21]. The standard
DCL screening approach must carry out the screening
of identical DCLs twice—with and without the target—
and then compare the equilibrium concentration pro-
files of all library ligands when generated in both the
absence and presence (following disruption of the li-
gand-target complexes) of target protein [4, 7, 10, 14 –
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DCL is the basis of identifying the “best binders”.
Unfortunately, this screening approach typically neces-
sitates synthesis of individual library components to
validate chromatographic (e.g., HPLC) or spectral (e.g.,
NMR) assignments; this is both labor- and time-inten-
sive and has the effect of undermining the promoted
advantages of DCC. The complexity of screening with
this indirect method also increases with the size of the
DCL owing to chromatographic and/or spectral over-
lap so that the preparation and screening of DCL
sub-libraries becomes necessary for deconvolution of
larger DCLs. For DCC to have a significant impact on
drug discovery will necessitate the development of a
direct screening protocol(s) for rapid identification and
characterization of those ligands with affinity for the
target protein, against the background of inactive DCL
constituents. It would be a tremendous advantage to
drug discovery applications of DCC if DCL screening
methodologies could proceed without the need for
chromatography, prior conversion to a static library,
preparation of sub-libraries, prior disruption of the
protein-ligand complexes, synthesis of individual li-
brary ligands to validate spectral assignments, or for the
preparation and duplicate screening of identical DCLs
(with and without the target).
The analytical demands of combinatorially gener-
ated compound libraries has directed the attention of
the pharmaceutical industry towards mass spectrome-
try owing to attributes of speed, intrinsic sensitivity,
specificity, low sample consumption, and capability of
resolving vast numbers of compounds in complex com-
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try for studying noncovalent native interactions between
proteins and ligands is also well established, and the
optimization of experimental parameters to reflect solu-
tion composition (and minimize non-specific complexes)
has been described [23–35]. On this basis, it was postu-
lated that integration of DCL synthesis with a mass
spectrometry based screen could fulfil the screening re-
quirements alluded to above and so provide an alternative
means for identifying the most effective combination of
building blocks in a DCL with a given target.
The target selected for the current study was the
enzyme carbonic anhydrase (CA) (EC 4.2.1.1). Modula-
tion of CAs has been exploited clinically for several
decades, however, more recently a role for CA inhibi-
tion as an anticancer therapy has been identified owing
to a predominance of some CA isoforms in cancer cells
and has again created interest in this enzyme as a
therapeutic target [36, 37]. Hydrazone exchange is now
one of the most promising reversible reactions for DCC
drug discovery applications [5, 6, 13, 19] as it may be
performed under reaction conditions that do not dis-
rupt the target proteins function or structure [38, 39],
and this reversible reaction was implemented here to
generate DCLs targeting CA (Scheme 1). This paper
describes the application of electrospray ionization Fou-
rier transform ion cyclotron resonance mass spectrom-
etry (ESI FTICR MS) to the direct screening of a DCL
generated by hydrazone exchange against the protein
target bovine carbonic anhydrase II (bCA II). The tech-
nique combines the attributes of ESI MS described
above and, in addition, exploits the capabilities of the
FTICR technique to selectively trap, then dissociate
these protein-ligand complexes to facilitate DCL ligand
identification [25, 26, 30].
Experimental
DCL Building Block Design
Building block 1, a benzene sulfonamide hydrazide,
was synthesized as the scaffold building block from
which to generate a DCL. Dual functionality was incor-
porated into the design of 1 to provide a scaffold with
both reliable bCA II affinity (aromatic sulfonamide) and
the capacity to take part in acyl hydrazone exchange
Scheme 1. Reversible hydrazone formation.(ArSO2NH2) is the primary recognition element for
small molecules to bind the active site of CA [40, 41].
Benzhydrazide (2) lacks the sulfonamide moiety of 1,
but is still able to participate in hydrazone exchange.
Control compound 2 was incorporated into the DCL as
a means of generating compounds expected to have no
affinity for the target bCA II. Five additional building
blocks A–E (each containing an aldehyde to act as the
hydrazone exchange partners of 1 and 2) were also
synthesized. Building blocks A–E were derived from
amino acids and were selected to introduce “tails” onto
1 to enable exploration of periphery recognition inter-
actions with bCA II that may complement the primary
bCA II interaction with the aromatic sulfonamide moi-
ety.
Chemistry
Building block 2 and all other synthetic reagents used
were purchased from Sigma-Aldrich. NMR spectra
were recorded at 25 °C on a Varian Gemini-200 (1H 200
MHz, 13C 50 MHz) NMR spectrometer. The 1H and 13C
chemical shifts were referenced to the solvent peak for
DMSO-d6 or CDCl3 at H 2.49 and C 39.5 or H 7.23 and
C 77.0, respectively. High-resolution mass spectra
(HRMS ESI) were recorded on a Bruker Daltonics Apex
III 47e FTICR mass spectrometer (Billerica, MA)
equipped with an Apollo ESI source. All solvents used
for chromatography and MS were Lab-Scan HPLC
grade (Dublin, Ireland), and the H2O used was Milli-
pore Milli-Q PF filtered (Billerica, MA). Flash chroma-
tography was performed on E. Merck Silica gel GF-60
(Darmstadt, Germany) grade silica (particle size 0.0400–
0.063 mm). Analytical thin-layer chromatography was
performed on 0.25 E Merck silica-gel plates (60-F-254).
Analysis of TLC was conducted using standard short-
wave UV, KMnO4 and ninhydrin stains, as appropriate.
Reaction yields less than 1 g were purified with
Varian mega bond elut (Palo Alto, CA) solid-phase
extraction columns (normal phase silica). Building
block 1was synthesized from 4-carboxybenzene sulfon-
amide [42]. Aldehyde building blocks A–E were syn-
thesized in two steps from commercially available(hydrazide moiety). An aromatic sulfonamide moiety amino acid methyl esters.
1076 POULSEN J Am Soc Mass Spectrom 2006, 17, 1074–1080(i) General synthetic method for amide coupling: A
solution of 4-carboxybenzaldehyde (0.5 g, 3.3 mmol),
EDCI (0.64 g, 3.3 mmol), and HOBT (0.38 g, 2.83 mmol)
in CH2Cl2 (10 mL) was stirred at room temperature for
20 min. To this activated carboxylic acid solution was
added the appropriate L-amino acid methyl ester hy-
drochloride (3.3 mmol) and one equivalent of diisopro-
pyl ethylamine (0.575 mL, 3.3 mmol). The reaction
mixture was stirred at room temperature overnight.
Workup involved washing with water (10 mL), 2M
Na2CO3 (10 mL) and water (10 mL). The final organic
fraction was dried over MgSO4, the solvent removed
and the crude material purified by solid-phase extrac-
tion on normal-phase silica sorbent using CH2Cl2 and
EtOAc as eluant. The pure chromatography fractions
were combined and the solvent removed to afford the
amide products as white solids. 2-(4-Formylbenz-
amido)acetic acid A= (yield 49%): 1H NMR (200 MHz,
DMSO-d6, ppm):  10.10 (s, 1H, CHO), 9.21 (t, 1H, J 
6.0 Hz, NH), 8.05 (m, 4H, CHarom), 4.06 (d, 2H, J  6.0
Hz, CH2), 3.67 (s, 3H, OCH3); HRMS (ESI) 222.076554.
Calculated for C11H12N1O4
: 222.076084. (S)-2-(4-
Formylbenzamido)propanoic acid B=: (yield 50%): 1H
NMR (200 MHz, CDCl3, ppm):  10.10 (s, 1H, CHO),
7.98 (m, 4H, CHarom), 6.89 (d, 1H, J 7.4 Hz, NH), 4.83
(m, 1H, CH), 3.83 (s, 3H, OCH3), 1.56 (d, 3H, J  6.8
Hz, CH3); HRMS (ESI) 236.091590. Calculated for
C12H14N1O4
: 236.091734. (S)-2-(4-Formylbenzamido)-3-
methylbutanoic acid C=: (yield 62%): 1H NMR (200
MHz, DMSO-d6, ppm):  10.08 (s, 1H, CHO), 8.87 (d,
1H, J  8.0 Hz, NH), 8.02 (s, 4H, CHarom), 4.31 (m, 1H,
CH), 3.35 (s, 3H, OCH3), 2.18 (m, 1H, CH), 0.98 (d,
3H, J  6.8 Hz, CH3), 0.93 (d, 3H, J  6.8 Hz, =CH3);
13C NMR (50 MHz, DMSO-d6, ppm):  19.7, 19.9 (CH3,
=CH3), 30.3 (CH), 52.4 (CH), 59.5 (OCH3), 129.1,
130.0, 138.6, 139.5 (ArCH), 167.0 (CO), 172.7 (CO), 193.6
(CO); HRMS (ESI) 264.123412. Calculated for
C14H18N1O4
: 264.123034. (S)-2-(4-Formylbenzamido)-4-
methylpentanoic acid D=: (yield 35%): 1H NMR (200
MHz, CDCl3, ppm):  10.06 (s, 1H, CHO), 7.93 (s, 4H,
CHarom), 6.90 (d, 1H, J  8.4 Hz, NH), 4.85 (m, 1H,
CH), 3.78 (s, 3H, OCH3), 1.63–1.81 (m, 3H, CH2 and
CH), 0.99 (m, 6H, CH3, =CH3); HRMS (ESI)
278.138804. Calculated for C15H20N1O4
: 278.138685. (S)-
2-(4-Formylbenzamido)-3-phenylpropanoic acid E=:
(yield 46%): 1H NMR (200 MHz, CDCl3, ppm):  10.09
(s, 1H, CHO), 7.92 (m, 4H, CHarom), 7.14–7.38 (m, 5H,
CHarom), 6.69 (d, 1H, J  7.4 Hz, NH), 5.13 (m, 1H,
CH), 3.82 (s, 3H, OCH3), 3.30 (m, 2H, CH2); HRMS
(ESI) 312.123376. Calculated for C18H18N1O4
:
312.123034.
(ii) General synthetic method for ester hydrolysis: To
a solution of A=–E= (0.3 mmol) in MeOH (5 mL) was
added 2.5 M NaOH (200 mL) and the reaction let to stir
at room-temperature overnight after which TLC analy-
sis confirmed complete hydrolysis of the ester. Workup
involved removal of MeOH followed by addition of 2.5
M HCl (200 L). A white precipitate formed and was
extracted into CH2Cl2 (10 mL). The organic fraction wasdried over MgSO4, the solvent removed and the crude
material triturated with diethyl ether, affording build-
ing blocks A–E as white solids. Methyl 2-(4-formylben-
zamido)acetate A (yield 61%): 1H NMR (200 MHz,
CDCl3, ppm):  10.12 (s, 1H, CHO), 8.01 (s, 4H, CHa-
rom), 6.68 (d, 1H, J  5.0 Hz, NH), 4.35 (d, 2H, J  5.0
Hz, CH2), 1.73 (br s, 1H, OH); HRMS (ESI) 206.045881.
Calculated for C10H8N1O4
: 206.045800. (S)-Methyl 2-(4-
formylbenzamido)propanoate B: (yield 57%): 1H NMR
(200 MHz, CDCl3, ppm):  10.11 (s, 1H, CHO), 7.99 (s,
4H, CHarom), 6.85 (d, 1H, J  7.4 Hz, NH), 4.86 (m, 1H,
CH), 3.39 (br s, 1H, OH), 1.63 (d, 3H, J  6.6 Hz, CH3);
HRMS (ESI) 220.061546. Calculated for C11H10N1O4
:
220.060899. (S)-Methyl 2-(4-formylbenzamido)-3-meth-
ylbutanoate C: (yield 81%): 1H NMR (200 MHz, CDCl3,
ppm): d 10.12 (s, 1H, CHO), 8.00 (s, 4H, CHarom), 6.70
(d, 1H, J  7.6 Hz, NH), 4.85 (m, 1H, CH), 2.42 (m, 1H,
CH), 2.20 (br s, 1H, OH), 1.10 (d, 3H, J  5.0 Hz,
CH3), 1.07 (d, 3H, J  5.0 Hz, CH3); HRMS (ESI)
248.092847. Calculated for C13H14N1O4
: 248.093721. (S)-
Methyl 2-(4-formylbenzamido)-4-methylpentanoate D:
(yield 79%): 1H NMR (200 MHz, CDCl3, ppm): d 10.10
(s, 1H, CHO), 7.98 (s, 4H, CHarom), 6.69 (d, 1H, J  7.6
Hz, NH), 4.89 (m, 1H, CH), 3.26 (br s, 1H, OH), 1.83
(m, 3H, CH2, CH), 1.03 (d, 6H, J  5.6 Hz, CH3,
=CH3); HRMS (ESI) 262.108497. Calculated for
C14H16N1O4
: 262.108791. (S)-Methyl 2-(4-formylbenz-
amido)-3-phenylpropanoate E: (yield 80%): 1H NMR
(200 MHz, CDCl3, ppm):  10.10 (s, 1H, CHO), 7.92 (m,
4H, CHarom), 7.29 (m, 5H, CHarom), 6.66 (d, 1H, J 7.0
Hz, NH), 5.14 (m, 1H, CH), 3.44 (br s, 1H, OH), 3.34
(m, 2H, CH2); HRMS (ESI) 296.092848. Calculated for
C17H14N1O4
: 296.093392.
Mass Spectrometry
The mass spectrometry presented in this paper was
performed on an APEX III 4.7 tesla FTICR mass spec-
trometer (Bruker Daltonics, Billerica, MA) fitted with an
Apollo ESI source operated in negative ion mode.
XMASS NT V7.0.2 mass spectrometry software on a PC
platform was used for data acquisition. Broadband
excitation was used to analyze a mass range from m/z
100–4500, with 256, 128, or 32 K data points acquired.
Samples were infused into the ESI source at 2 mLmin1.
Nitrogen was used as both the drying gas (125 °C) and
nebulizing gas. Relevant parameters include the ESI
source pressure (6.2  107 mbar), high vacuum ana-
lyzer region pressure (1.3  1010 mbar) and hexapole
accumulation time of 1 s. MS/MS experiments were
performed by sustained off-resonance irradiation colli-
sion activated dissociation (SORI-CAD) using argon as
the collision gas at an analyzer pressure of 108 mbar
(argon inlet pressure 2.9  102 mbar). The parent ions
were selected by use of correlated sweep isolation. The
CAD collision energy was tuned to cause dissociation of
the noncovalent protein-ligand complexes. Agilent ES
tuning mix (catalog number G2421A, Palo Alto, CA)
was used for an external four-point calibration.
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CA II from bovine erythrocytes was obtained from
Sigma-Aldrich, catalog number C2522, lot number
044K6064. A 30 M solution of bCA II was prepared in
10 mM NH4OAc (pH 7.2), aliquots of the protein
solution were either used immediately or stored at
20 °C. Generation of the in situ DCL of acyl hydra-
zones 1A–1E and 2A–2E was achieved by incubation of
1, 2, and A–E in the presence of bCA II (conditions (i) of
Scheme 2). bCA II (30 M) was mixed with 1 (15 M),
2 (15 M), and A–E (6 M each), with 1% DMSO to
effect solubility, at 37 °C for 40 h. The total theoretical
hydrazone concentration was equivalent to the concen-
tration of bCA II. Preformed hydrazones were gener-
ated by the reaction of A–E (2 mM each), with hydra-
zides 1 (5 mM) and 2 (5 mM), respectively, in DMSO as
solvent (reaction volume 100 L) and amberlite resin
IRN 120 H (5 mg) as acid catalyst (pH 4) (conditions
(ii) of Scheme 2). Hydrazone exchange was rapid (2 h)
as evidenced by loss of 1H NMR signals for the alde-
hyde protons of A–E (monitored with reactions carried
out in DMSO-d6). An aliquot of the pre-equilibrated
DCL (to give a final hydrazone concentration of 30 M
in 1% DMSO) was then added to an aliquot of bCA II.
Both the in situ and pre-equilibrated DCLs were screened
using mass spectrometry, the sample quantity consumed
for the MS/MS experiment was less than 100 L.
Results and Discussion
Confirmation of Reversibility of Hydrazone
Exchange
Aqueous ammonium acetate is a “volatile buffer” suit-
able for ESI MS applications to study native protein-
ligand noncovalent complexes. This buffer (pH 7.2) has
not before been used for hydrazone exchange and so
preliminary for this study was confirmation that hydra-
zone exchange was indeed dynamic under the condi-
Scheme 2. Generation of a DCL of acyl hydrazo
2 (15 M), A–E (6 M each), 10 mM NH4 OAc
conditions: 1 (10 mM) or 2 (10 mM), A–E (2 mM
rt, 24 h.
Table 1. Hydrazone solutions prepared to demonstrate dynami
Solution Hydrazide (200 M) Aldehyde (200 M) Hy
(i) 1 B
(ii) 2 E
(iii) 1 E
(iv) 2 Btions as used for subsequent MS investigations (hydra-
zone exchange is rapid at acidic pH). Solutions (i) to
(iv), each containing a unique hydrazide/aldehyde
combination, were prepared in 10 mM NH4OAc, 1%
DMSO (pH 7.2), and incubated at 37 °C for 40 h. The
formation of expected hydrazone products was con-
firmed by negative ion ESI MS (Table 1). Less than 5%
free hydrazide or aldehyde was detectable.
Solutions (i) and (ii) were then combined (Mix 1 
1B, 2E) as were solutions (iii) and (iv) (Mix 2  1E, 2B),
and incubated (without agitation) at 37 °C (Scheme 3).
The hydrazone composition of both mixes was moni-
tored over time by ESI FTICR MS analysis (Figure 1).
Initially, only the original hydrazones were present in
solution (Figure 1a), but over time the rearranged
hydrazones 1E and 2B appeared in Mix 1 and rear-
ranged hydrazones 1B and 2E appeared in Mix 2
(Figure 1b– d). This experiment confirmed that hydra-
zone exchange was reversible under the neutral condi-
tions used for the native ESI FTICR MS screening.
Screening of DCLs Using Mass Spectrometry
ESI FTICR MS analysis of bCA II in aqueous ammo-
nium acetate yielded the ESI negative ion mass spec-
trum of Figure 2a. Peaks corresponding to the 8  to 10
charge states of bCA II were observed, with the 9
charge state predominating. This charge state envelope
(low charge states and few charge states) is typical for
bCA II when in a compact, tightly folded native struc-
ture [25–27]. The mass spectrum of the DCL prepared
from 1, 2, and A–E in the presence of bCA II (conditions
(i) of Scheme 2) is presented in Figure 2b. The same
charge state envelope as for bCA II (Figure 2a) was
observed, however each charge state now consisted of a
grouping of peaks: a peak that corresponded to native
bCA II and at higher m/z value a group of peaks that
corresponded to bCA II-hydrazone complexes [bCA
II-1A–1E] as well as a small amount of [bCA II-1]. The
(i) in situ conditions: bCA II (30 M), 1 (15 M),
7.2), 1% DMSO, 37 °C for 40 h. (ii) Preformed
), DMSO, amberlite resin IRN 120 H, pH 4,
razone exchange
ne product  [M]
Molecular weight
calculated for
[M  H] (Da)
Molecular weight
observed for
[M  H] (Da)
1B 417.09 417.09
2E 414.15 414.15
1E 493.12 493.12nes.
(pH
eachc hyd
drazo2B 338.11 338.11
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zones 1A–1E and 2A–2E (generated by acid catalysis
before incubation with bCA II, conditions (ii) of Scheme
2) was essentially identical to Figure 2b, differing only
by the absence of the [bCA II-1] complex. Acid cata-
lyzed hydrazone exchange is extremely rapid and all of
the hydrazide scaffold 1 is consumed under these
Scheme 3. Hydrazone mixes utilized for confirm
Mix 2.
a)
1E
2B2E 1B
b)
2E 1B
1E
2B
c)
d)
1E
2E 1B
1E
2B 2E 1B
2B
350   400  450   500   350  400  450    500
m/z m/z
Figure 1. ESI FTICR negative ion mass spectrum of hydrazone
Mix 1 (LHS) and hydrazone Mix 2 (RHS). (a) Fifteen min after Mix
1 and Mix 2 were combined. (b) Two days after Mix 1 and Mix 2
were combined. (c) Four days after Mix 1 and Mix 2 were
combined. (d) Seven days after Mix 1 and Mix 2 were combined.conditions so that a complex for [bCA II-1] is not
observed.
Owing to overlapping isotopic envelopes, a conse-
quence of the size of bCA II (29 kDa), the [bCA
II-hydrazone] complexes were not completely resolved
(Figure 2b insert) and the MS/MS technique was em-
ployed to confirm the identity of the bound ligands
from the ten possible hydrazone ligands accessible in
n of dynamic hydrazone exchange. (a) Mix 1. (b)
Figure 2. (a) ESI FTICR negative ion mass spectrum of bCA II (30
M) from 10 mM NH4OAc solution, 1% DMSO. (b) ESI FTICR
negative ion mass spectrum of a mixture of bCA II (30 M) and
DCL containing ten possible hydrazone products in 10 mM
NH4OAc, 1% DMSO. (c) MS/MS spectrum obtained following
collision activated dissociation (CAD) of [bCA II-hydrazone] non-atiocovalent complexes.
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state was followed by collision activated dissociation
(CAD) resulting in dissociation of the noncovalent
complexes (Figure 2c) to yield unbound bCA II, both 8
and 9 charge states, and—important the for applica-
tion to DCC screening—singly charged negative ions
for the hydrazone ligands, now well resolved by mo-
lecular mass with m/z values between 400 and 500
(Figure 2c). The masses of these ions were consistent
with the [M  H] ions expected for the DCL sulfon-
amide hydrazone products 1A–1E (Table 2). No ions in
the MS/MS spectrum could be attributed to hydrazones
2A–2E (lacking the sulfonamide moiety). As only hy-
drazides (1 and 2) and aldehydes (A– E) were incubated
with the target protein the hydrazones identified from
the DCL with affinity for bCA II must have been
synthesized in situ by DCC. These results demonstrate
that the MS screening approach was able to directly
identify ligands of interest from a DCL while in the
presence of the target protein without the need for any
prior workup.
Validation of Mass Spectrometry Screening Results
by a Conventional Enzyme Assay
A conventional solution phase competitive binding
assay [43– 45] for bCA II was used to measure the
equilibrium dissociation constants (Ki’s) for the com-
pounds described in this study. The fluorescence-based
assay relies on the competition for the active site of
bCAII between the ligand 5-(dimethylamino)-1-naptha-
lenesulphonamide (DNSA) and the test compound [45].
Upon excitation at 290 nm (an absorption minimum for
DNSA) fluorescence is detected at 460 nm (from the
bCAII-DNSA complex). Each of the DCL hydrazones
1A–1E, 2A–2E, as well as building blocks 1 and 2, and
aldehydes A–E were individually assessed for their
ability to inhibit the binding of DNSA to the active site
of bCA II. As expected 2, 2A–2E, and aldehydes A–E
(each lacking the sulfonamide moiety) showed no com-
petitive inhibition of DNSA binding even at ligand
concentrations up to 100 M. The equilibrium dissoci-
ation constants (Ki’s) measured for sulfonamides 1 and
1A–1E are given in Table 3. The DCL products 1A–1E
each exhibited increased affinity for the enzyme (Ki
Table 2. Molecular weights for bCA II bound ligands
identified from in situ screening of the DCL by ESI FTICR MS
Molecular weight
observed
[M  H] (Da)a Compound  [M]
Molecular weight
calculated for
[M  H] (Da)
403.06 1A 403.07
417.07 1B 417.09
445.10 1C 445.12
459.11 1D 459.13
493.09 1E 493.12
aObserved molecular weights taken from mass spectrum of Figure 2,
entry c.range 10.6–82.3 nM) when compared to the scaffold
building block 1 (Ki  150 nM). These conventional
assay results were in complete agreement with bCA II
ligand affinity as determined in the mass spectral screen
as only those ligands with affinity for bCA II (i.e., 1,
1A–1E) formed noncovalent complexes with bCA II
under the native ESI mass spectrum conditions em-
ployed. Hydrazone linked sulfonamide-amino acid
conjugates represent a new class of potent bCA II
inhibitors.
Conclusions
In conclusion, a single and rapid (minutes) mass spec-
trometry experiment has permitted concurrent identifi-
cation of all ligands of interest from a DCL in the
presence of the protein target, without the need for any
prior workup. This direct approach integrates DCL
synthesis with screening and offers an attractive single
analysis alternative to the current ligand enrichment
screening methodology. The approach readily distin-
guishes the effective (from ineffective) combination of
building blocks in the DCL by detection of specific
protein-ligand noncovalent complexes. Comparison
with a conventional enzyme assay was fully consistent
with the MS result. It is reasonable to expect that
increased DCL size need not increase the complexity of
this screening protocol, owing to the sensitivity, high-
resolution, and MS/MS capabilities of the FTICR MS
technique, this should avoid the need for multiple
sub-libraries to deconvolute larger DCLs. This mass
spectrometry screening approach may provide a fast
preliminary DCL screen to identify candidates for later
verification with more traditional but time-consuming
approaches as so may better equip DCC for the screen-
ing challenges and demands of modern drug discovery
programs.
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Table 3. bCA II competitive binding assay results for 1, 1A-1E,
and standard bCA II inhibitors acetazolamide and
sulphanilamide expressed as Ki in nM
Compound bCA II Ki (R2)a
1 150.0 (0.98)
1A 65.9 (0.97)
1B 10.6 (0.98)
1C 69.3 (0.97)
1D 82.3 (0.97)
1E 22.5 (0.98)
Acetazolamide 6.9 (0.96)
Sulfanilamide 1690 (0.97)
abCA II binding data utilizing competitive displacement of DNSA from
bCA II.LE237908) and Griffith University.
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